A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2019
Price : $35 *
At a glance
- Drugs Abatacept (Primary)
- Indications Interstitial lung diseases; Myositis
- Focus Proof of concept; Therapeutic Use
- Acronyms ATtackMy-ILD
- 12 Feb 2019 Planned End Date changed from 1 Oct 2019 to 1 May 2021.
- 12 Feb 2019 Planned primary completion date changed from 1 Apr 2019 to 31 Dec 2020.
- 09 Oct 2017 Status changed from not yet recruiting to recruiting.